Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety Study of Oral ZSTK474 in Patients With Cancer

This study has been completed.
Information provided by (Responsible Party):
Zenyaku Kogyo Co., Ltd. Identifier:
First received: January 18, 2011
Last updated: January 15, 2015
Last verified: January 2015

January 18, 2011
January 15, 2015
January 2011
December 2013   (final data collection date for primary outcome measure)
Maximum tolerated dose [ Time Frame: 21 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01280487 on Archive Site
Pharmacokinetics [ Time Frame: 21 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
A Safety Study of Oral ZSTK474 in Patients With Cancer
A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects With Advanced Solid Malignancies
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of daily oral doses of ZSTK474, an oral phosphatidylinositol 3-kinase (PI3K) inhibitor, in subjects with advanced solid malignancies.
Not Provided
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Drug: ZSTK474
Daily oral dosing for 21 days each cycle
Experimental: Oral ZSTK474
Daily oral dosing for 21 days per cycle
Intervention: Drug: ZSTK474
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2014
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or females ≥18 years of age;
  2. Histologically-confirmed advanced (metastatic or unresectable) solid tumor - for which available therapy is not effective;
  3. ECOG performance status score of ≤2 and an expected survival of >8 weeks;
  4. Recovered from the toxicities of prior chemotherapy, radiotherapy, and other cancer therapies; all toxicities must be determined to be below Grade 2 (assessed using the NCI CTCAE v4.0).
  5. Adequate blood counts with a hemoglobin (Hgb) of ≥9.0 mg/dL, absolute neutrophil count (ANC) >1,500/mm3, and platelets ≥100,000/mm3 (all without transfusion support);
  6. Subjects who are willing and able to provide written informed consent.

In the expanded cohort at the MTD only: Subjects must be willing to undergo mandatory biopsies of tumor tissue twice during the first cycle (before and during dosing) and must have tumor tissue in a location accessible to incisional biopsy of a superficial lesion or percutaneous core needle biopsy on an outpatient basis without undue risk to the subject.

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding;
  2. Men or women of reproductive potential who are not willing to use acceptable means of contraception while on study drug and for an additional 90 days after the last dose of study drug;
  3. Body Mass Index (BMI) is ≥30 kg/m2;
  4. Have primary central nervous system (CNS) tumors or untreated/uncontrolled CNS metastases; Note: Subjects with stable/controlled CNS metastases may be enrolled (i.e., if CNS lesions have been stable in size for at least one month and the subject is off steroid and anti-convulsants).
  5. Have received any investigational interventional agents within the 4 weeks prior to the start of dosing with ZSTK474;
  6. Are receiving concurrent anti-tumor chemotherapy, radiotherapy, or immunotherapy - or have received any of these non-investigational agents within the previous 4 weeks or 5-half-lives (whichever is longer) prior to the start of dosing with ZSTK474;
  7. Are not able or willing to comply with the study procedures, including the study visit schedule;
  8. Have previously been treated with a phosphatidylinositol 3 kinase (PI3K) inhibitor;
  9. Have serious or significant intercurrent illnesses or underlying diseases, such as:

    1. Diabetes
    2. Gastrointestinal disorder
    3. Hepatic: AST or ALT >2.5 x ULN (or >5.0 x ULN with liver metastases) or serum bilirubin >1.5 x ULN;
    4. Renal (acute or chronic renal disease or eGFR <55 mL/min)
    5. Cardiovascular:

      • Uncontrolled hypertension or blood pressure >140/90 mmHg;
      • Symptomatic congestive heart failure;
      • Myocardial infarction within the past 6 months;
      • Unstable angina pectoris;
      • Cardiac arrhythmia;
      • Congenital long QT syndrome;
      • QTc >450 msec for men or >470 msec for women.
    6. Other:

      • Known diagnosis of HIV infection;
      • Other ongoing or active infections;
      • Psychiatric illness, substance abuse or social situation that would preclude study compliance.
      • Other serious concurrent illness that would preclude assessment of drug effect;
      • PT/PTT)/APTT/INR >ULN for subjects not on anti-coagulants; INR > 1.5 x ULN for subjects on low dose warfarin.
  10. Current treatment with the following drugs:

    • any anti-seizure medications;
    • therapeutic anti-coagulant doses of warfarin.
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Zenyaku Kogyo Co., Ltd.
Zenyaku Kogyo Co., Ltd.
Not Provided
Principal Investigator: Craig Lockhart, MD Washington University School of Medicine
Principal Investigator: Anthony Olszanski, MD Fox Chase Cancer Center
Principal Investigator: Geoffrey Shapiro, MD PhD Dana-Farber Cancer Institute
Zenyaku Kogyo Co., Ltd.
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP